STING1 and neoplasm: These systems can respond to specific biochemical changes in the tumor microenvironment (TME), such as hypoxia, pH, redox potential, or enzymes, as well as external stimuli including light, magnetic fields, or electrical signals.[13] This precise control over drug activation and release enhances therapeutic efficacy while minimizing off‐target effects and immune‐related toxicities, which is particularly crucial for potent STING agonists known to cause severe dose‐limiting toxicities.